In vitro and in vivo studies of the Interferon-alpha action on distinct Orthobunyavirus

Antiviral Research

Volumn 75, Issue 2, 2007, Pages 121-128

  Livonesi, Márcia Cristina ^a   Moro de Sousa, Ricardo Luiz ^b   Badra, Soraya Jabur ^a   Figueiredo, Luiz Tadeu Moraes ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bunyaviridae; Interferon alpha; Orthobunyavirus; Plaque assay; Suckling mice

Indexed keywords

ALPHA INTERFERON A; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; MOUSE; NONHUMAN; ORTHOBUNYAVIRUS; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANIMALS, SUCKLING; ANTIVIRAL AGENTS; BODY WEIGHT; BRAIN; BUNYAVIRIDAE INFECTIONS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERFERON ALFA-2A; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; MICE; ORTHOBUNYAVIRUS; SURVIVAL RATE; TIME FACTORS; VERO CELLS; VIRUS REPLICATION;

BUNYAVIRIDAE; GUAROA VIRUS; MUS; OROPOUCHE VIRUS; ORTHOBUNYAVIRUS; REYNOSIA GUAMA;

EID: 34247613489     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.01.158     Document Type: Article

References (39)

1. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15 (1997) 749-795
2. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., and Haller O. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J. Virol. 75 3 (2001) 1371-1377
3. Brinton M.A., Gavin E.I., Lo W.K., Pinto A.J., and Morahan P.S. Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection. Antiviral Res. 20 2 (1993) 155-171
4. Crance J.M., Gratier D., Guimet J., and Jouan A. Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds. Res. Virol. 148 (1997) 353-365
5. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., Albrecht J., and International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339 (1998) 1493-1499
6. Diamond M.S., Roberts T.G., Edgil D., Lu B., Ernst J., and Harris E. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74 11 (2000) 4957-4966
7. Elliot R.M., Calisher C.H., Goldbach R., Moyer J.T., Nichol S.T., Pettersson R., Plyusnin A., and Schmaljohn C.S. Bunyaviridae. In: Fauquet C.M., van Regenmortel M.H.V., Bishop D.H.L., Carstens E.B., Estes M.K., Lemon S.M., Maniloff J., Mayo M.A., McGooch D.H., Pringle C.R., and Wickner R.B. (Eds). Virus Taxonomy. Seventh Report of the International Committee on Taxonomy of Viruses (2000), Academic Press Inc., San Diego, CA 599-621
8. Foster G.R., and Finter N.B. Are all Type I human interferons equivalent?. J. Viral Hepatitis 5 (1998) 143-152
9. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., and Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep. 50 (1966) 219-244
10. Galligan C.L., Murooka T.T., Rahbar R., Baig E., Majchrzak-Kita B., and Fish E.N. Interferons and viruses: signaling for supremacy. Immunol. Res. 35 (2006) 27-29
11. Goldsmith C.S., Elliot L.H., Peters C.J., and Zaki S.R. Ultrastructural characteristics of Sin Nombre virus, causative agent of hantavirus pulmonary syndrome. Arch. Virol. 140 (1995) 2107-2122
12. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81 (2000) 2341-2364
13. Iversson L.B. Current status of the eco-epidemiological knowledge on arboviruses pathogenic to humans in the Atlantic Forest region of the State of São Paulo. Rev. Inst. Med. Trop. São Paulo 36 (1994) 343-353
14. Iversson L.B., Silva R.A.M.S., Travassos Da Rosa A.P.A., and Barros V.L.R.S. Circulation of Eastern Equine Encephalitis, Western Equine Encephalitis, Ilhéus, Maguari, and Tacaiuma viruses in equines of the Brazilian Pantanal, South America. Rev. Inst. Med. Trop. São Paulo 35 (1993) 355-359
15. Jonkers A.H., Spence L., and Olivier O. Laboratory studies with rodents and native to Trinidad. Am. J. Trop. Med. Hyg. 17 (1968) 299-307
16. LeDuc J.W., and Pinheiro F.P. Oropouche fever. In: Monath T.P. (Ed). The Arboviruses: Epidemiology and Ecology vol. IV (1988), CRC Press, Boca Raton, FL 1-15
17. Léonard V.H.J., Kohl A., Hart T.J., and Elliot R.M. Interation of Bunyamwera Orthobunyavirus NSs protein with mediator protein MED8: a mechanism for inhibiting the interferon response. J. Virol. 80 19 (2006) 9667-9675
18. Liu G., Zhai Q., Schaffner D.J., Wu A., Yohannes A., Robinson T.M., Maland M., Wells J., Voss T., Bailey C., and Alibek K. Prevention of letal respiratory vaccinia infections in mice with interferon-α and interferon-γ. FEMS Immunol. Med. Microbiol. 40 (2004) 201-206
19. Livonesi M.C., Moro de Sousa R.L., Badra S.J., and Figueiredo L.T.M. In vitro and in vivo studies of the ribavirin action on Brazilian Orthobunyavirus. Am. J. Trop. Med. Hyg. 75 5 (2006) 1011-1016
20. Mahanty S., Gupta M., Paragas J., Bray M., Ahmed R., and Rollin P.E. Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 312 (2003) 415-424
21. March R.W., and Hetrick F.M. Studies on Guaroa virus. Am. J. Trop. Med. Hyg. 16 (1967) 191-195
22. Márquez-Peiró J.F., Pérez-Peiró C., Carmena-Carmena J., and Jiménez-Torres N.V. Identificación de oportunidades de mejora del tratamiento de la hepatitis C. Farm. Hosp. 30 3 (2006) 154-160
23. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K., and Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339 (1998) 1485-1492
24. Morens D.M., Halstead S.B., Repik P.M., Putvatana R., and Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J. Clin. Microbiol. 22 2 (1985) 250-254
25. Mosca J.D., and Pitha P.M. Transcriptional and posttranscriptional regulation of exogenous human beta Interferon gene in simian cells defective in Interferon synthesis. Mol. Cell Biol. 6 (1986) 2279-2283
26. Pinheiro F.P., Travassos Da Rosa A.P.A., and Vasconcelos P.F.C. Oropouche fever. In: Feigin R.D. (Ed). Textbook of Pediatric Infectioius Diseases (2004), W.B. Saunders Co., Philadelphia 2418-2423
27. Platanias L.C., Uddin S., Domanski P., and Colamonici O.R. Differences in interferon α and β signalling. J. Biol. Chem. 271 (1996) 23630-23633
28. Schmutz J.L., Barbaud A., and Trechot P. Side effects of interferon alpha2a and b. Ann. Dermatol. Venereol. 131 (2004) 422
29. Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 55 (2001) 255-281
30. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
31. Stetson D.B., and Medzhitov R. Type I interferons in host defense. Immunity 25 (2006) 373-381
32. Ströher U., DiCaro A., Li Y., Strong J.E., Aoki F., Plummer F., Jones S.M., and Feldmann H. Severe acute respiratory syndrome-related Coronavirus is inhibit by interferon-α. J. Infect. Dis. 189 (2004) 1164-1167
33. Tan E.L.C., Ooi E.E., Lin C., Tan H.C., Ling A.E., Lim B., and Stanton L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10 4 (2004) 581-586
34. Tavares-Neto J., Freitas-Carvalho J., Nunes M.R., Rocha G., Rodrigues S.G., Damasceno E., Darub R., Viana S., and Vasconcelos P.F. Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine. Rev. Soc. Bras. Med. Trop. 37 1 (2004) 1-6
35. The Italian Cooperative Study Group on CML. IFN-α2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330 (1994) 820-825
36. Travassos da Rosa A.P.A., Travassos da Rosa J.F.S., Pinheiro F.P., and Vasconcelos P.F.C. In: Leão R.N.Q. (Ed). Doenças Infecciosas e Parasitárias-Enfoque Amazônico (1997), CEJUP, Belém 207-241
37. Watts D.M., Phillips I., Callahan J.D., Greibenow W., Hyams K.C., and Hayes C.G. Oropouche virus transmission in Amazon river basin of Peru. Am. J. Trop. Med. Hyg. 56 (1997) 148-152
38. Weber F., Bridgen A., Fazakerley J.K., Streitenfeld H., Kessler N., Randall R.E., and Elliott R.M. Bunyamwera bunyavirus nonstructural protein NSs counteracts the induction of alpha/beta interferon. J. Virol. 76 16 (2002) 7949-7955
39. Yeow W., Lawson C.M., and Beilharz M.W. Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces Cytomegalovirus replication. J. Immunol. 160 (1998) 2932-2939